Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22046

Title:	Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Authors:	Garcia-Alfonso, Pilar Chaves, Manuel Muñoz, Andrés Salud, Antonieta García-Gonzalez, Maria Grávalos, Cristina Massuti, Bartomeu González-Flores, Encarna Queralt, Bernardo López-Ladrón, Amelia Losa, Ferran Gómez, Maria Jose Oltra, Amparo Aranda, Enrique View more
Mesh:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Bevacizumab Camptothecin Capecitabine Colorectal Neoplasms Disease-Free Survival Female Humans Irinotecan Male Middle Aged Neoplasm Metastasis Treatment Outcome View more
Issue Date:	29-Apr-2015
Citation:	BMC Cancer.2015 Apr;(15):327
Abstract:	The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC.
PMID:	25925749
URI:	https://hdl.handle.net/20.500.12530/22046
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC4423590.pdf		611.34 kB	Adobe PDF	View/Open